Terns Pharmaceuticals to Present at the H. C. Wainwright 6th Annual NASH Investor Conference

Rhea-AI Summary

Terns Pharmaceuticals, based in Foster City, is set to present at the H. C. Wainwright 6th Annual NASH Investor Conference on October 17, 2022, at 11:30 a.m. ET. The company focuses on developing small-molecule therapies targeting serious diseases, including oncology, obesity, and non-alcoholic steatohepatitis (NASH). A live webcast of the presentation will be available on their investor relations page, with a replay accessible for 30 days. Terns' pipeline includes multiple clinical-stage programs aimed at serious health conditions.

FOSTER CITY, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that management will be presenting at the H. C. Wainwright 6th Annual NASH Investor Conference on Monday, October 17 at 11:30 a.m. ET.

A live webcast of the presentation will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcast will be archived on Terns’ website for 30 days following the presentation.

About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and NASH. Terns’ pipeline includes four clinical stage development programs including an allosteric BCR-ABL inhibitor, a THR-β agonist, an FXR agonist, a VAP-1 inhibitor, and a preclinical small-molecule GLP-1 receptor agonist program. For more information, please visit: www.ternspharma.com.

Contacts for Terns

Investors
Justin Ng
investors@ternspharma.com

Media
Jenna Urban
Berry & Company Public Relations
media@ternspharma.com

FAQ

When is Terns Pharmaceuticals presenting at the NASH Investor Conference?

Terns Pharmaceuticals will present at the H. C. Wainwright 6th Annual NASH Investor Conference on October 17, 2022, at 11:30 a.m. ET.

Where can I watch Terns Pharmaceuticals' presentation?

The presentation can be watched live on Terns Pharmaceuticals' investor relations page at http://ir.ternspharma.com.

What is the focus of Terns Pharmaceuticals' development programs?

Terns Pharmaceuticals is focused on developing small-molecule therapies for oncology, obesity, and non-alcoholic steatohepatitis (NASH).

How long will the webcast replay of Terns Pharmaceuticals' presentation be available?

The replay of Terns Pharmaceuticals' presentation will be available for 30 days after the event.

What types of programs does Terns Pharmaceuticals have in its pipeline?

Terns Pharmaceuticals' pipeline includes clinical-stage development programs such as an allosteric BCR-ABL inhibitor, THR-β agonist, FXR agonist, and VAP-1 inhibitor.